Takeda Signs a Multi-Target Agreement with StrideBio to Develop Gene Therapies for Neurological Disorders

Takeda Signs a Multi-Target Agreement with StrideBio to Develop Gene Therapies for Neurological Disorders

 Shots:

  • StrideBio to receive $30M upfront & near term pre-clinical milestones, $680M as development and commercial milestones & royalties on global sales of products. Takeda to get rights for clinical development and commercialization of selected products developed
  • StrideBio will take care of preclinical development & manufacturing of in vivo AAV based gene-therapies for Takeda’s three targets including Friedreich’s Ataxia (FA)
  • StrideBio’s gene therapy technology is used to develop adeno-associated viral (AAV) therapies for rare diseases able to evade pre-existing antibodies. In 2018, Takeda Ventures funded Stride Bio for the development of AAV technology

Click here to read full press release/ article | Ref: Mitsubishi Tanabe Pharma | Image: MGH